Search

for
Search:

Learn

0 / 0 results

— no results

Research

5 / 262 results

research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Premenopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

1 citations , July 2021 in “Frontiers in Oncology”

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.

Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study

research Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study

June 2024 in “Journal of Clinical Oncology”

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

research Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

4 citations , October 2018 in “Asia-Pacific Journal of Clinical Oncology”

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

research The Comparative Safety of Epirubicin and Cyclophosphamide Versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial

8 citations , June 2022 in “Cancers”

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

A Plain Language Summary of Quality of Life with Sacituzumab Govitecan Treatment in the TROPiCS-02 Study in Participants with Breast Cancer (HR-Positive/HER2-Negative)

research A Plain Language Summary of Quality of Life with Sacituzumab Govitecan Treatment in the TROPiCS-02 Study in Participants with Breast Cancer (HR-Positive/HER2-Negative)

March 2025 in “Future Oncology”

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

View more "her2-negative" in research →

Community Join

2 / 2 results

community My mother has been losing hair as of recently (she's approaching 60). What are the best supplements and medications I could buy for her to help her with thinning hair, apart from high quality multivitamin, collagen with hyaluronic acid, omega-3s and other basics?

in Treatment 2 upvotes 1 year ago

A user seeks advice on treatments for his mother's hair loss, considering Minoxidil, Finasteride, and shampoos. The mother is being monitored for breast cancer, which may be relevant.

community Hair loss and ethnicity - Caucasian men the most likely to experience hair loss

in Chat 17 upvotes 3 years ago

The conversation discusses how Caucasian men are more likely to experience hair loss due to genetic predisposition, with factors like the androgen receptor on the X chromosome playing a significant role. The user also expresses confusion about the evolutionary reasons for hair loss, especially in colder climates where it would seem beneficial to retain hair for warmth.